Inova Schar Cancer Institute signs partnership for ASCO's groundbreaking TAPUR clinical trial.
M2 EQUITYBITES-October 6, 2017-Inova Schar Cancer Institute signs partnership for ASCO's groundbreaking TAPUR clinical trial
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Personalised health company Inova Schar Cancer Institute reported on Thursday the launch of a partnership to recruit patients for the American Society of Clinical Oncology's (ASCO) first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
The TAPUR trial will evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of these drugs outside of those already approved by the US Food and Drug Administration (FDA).
In conjunction, the patients enrolled in the study will have access to these cancer drugs at no cost. The eligible participants include those who have an advanced solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefiting from standard anti-cancer treatments or for whom no acceptable standard treatment is available.
An Institutional Review Board has approved the study and ASCO has established a Steering Group and an independent Data and Safety Monitoring Board to oversee the trial. A Molecular Tumor Board is available to help identify treatment options for patients based on the genomic profile of their tumor.
Concurrently, ASCO will publish the study's findings in peer-reviewed journals to inform clinical practice and future research.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Oct 6, 2017|
|Previous Article:||QIAGEN unveils fourth-generation QuantiFERON-TB Gold Plus in the US.|
|Next Article:||Genmab grants restricted stock units and warrants to employees.|